Aesica and Bespak unveil new single source supply chain solution for drug and delivery device manufacturing services

Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today unveiled the industry’s first single source supply chain solution for drug and delivery device development, formulation, manufacturing and packaging. This new business model has been brought to the market following Consort Medical’s acquisition of Aesica. It adds value to the company’s existing model in which Aesica takes on the management of other CDMOs, whilst serving as the single, central point of customer contact.

Consort Medical has combined and integrated Aesica’s drug formulation, manufacturing and packaging capabilities with Bespak’s delivery device development and manufacturing services. This has created a global single source drug and device contract manufacturing partner for pharmaceutical customers. The full range of services that the Group now provides includes finished dose manufacturing, formulation development, API development and manufacture for drugs, together with pilot to high volume manufacturing, prototype development and design for manufacture and concept generation for devices.

Aesica and Bespak have strong synergies and similarities across quality control, regulatory compliance and reliable manufacturing. This includes QP release and ISO certified Quality Management Systems, cGMP compliance and operating to FDA and MHRA standards of approval. Furthermore, both companies comply with environmental and health and safety standards. Aesica provides secure facilities that handle up to schedule 2 controlled substances, together with a high containment suite capable of manufacturing products in the SafeBridge category 3 potency level, whilst Bespak is accredited with ISO 14001.

Both brands provide pilot up to volume manufacturing – operating at scales from grams to full scale manufacture of drugs and low hand machine production through to high volume device assembly. In addition, continuous improvement tools underpin each company’s operations. Moreover, Aesica and Bespak offer complex solutions and capabilities ranging from semi continuous processing, high capacity and high potent drug manufacturing through to 6-Sigma quality on high volume components and devices.

Ian Muir, Managing Director of Aesica Pharmaceuticals and Keyvan Djamarani, Managing Director of Bespak commented: “Our highly innovative business model, which optimises drug and device services in a single group, serves to streamline and accelerate our pharmaceutical partners’ route to market and, at the same time, to reduce the cost and complexity of drug and device development. We confidently believe that the demand from the market for a single source service offering from a single provider will increase.”

About Consort Medical:

  • Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities
  • The Consort medical Group has facilities in King’s Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead in the UK; in Monheim and Zwickau, Germany; in Pianezza, Italy.

About Aesica

  • Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

About Bespak:

  • Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 7203 6740/6745 or e-mail;

  • News
  • Case Studies
  • Pages
  • Blogs
  • Locations
  • Experts